BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update

Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in revenue driven by its NGAL product line, particularly in the U.S. market [1][4][6]. Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][7]. - For the fiscal year 2025, total revenue was DKK 40.3 million, an 11% increase from DKK 36.2 million in 2024, with a 13% growth at constant exchange rates [3][7]. - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% increase from the previous year [3][7]. - The adjusted EBITDA loss for FY 2025 is estimated at DKK 77 million, aligning with the guidance of a loss between DKK 75-80 million [3][7]. 2026 Financial Guidance - For 2026, BioPorto expects total revenue to be between DKK 48-58 million, representing a growth of 20-45% [6][8]. - Total NGAL revenue is projected to grow by 20-50%, reaching DKK 33-42 million [6][8]. - The adjusted EBITDA loss for 2026 is anticipated to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [8]. Business Strategy and Market Adoption - The company is focused on executing its "Forward" strategy, aiming to increase market adoption of its NGAL test, with a target of over 60 active hospitals in the U.S. by the end of 2026 [6][10][12]. - By the end of 2025, BioPorto had established 44 active hospitals for NGAL RUO, an increase of 8 from the previous year [12]. - The company is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [12]. Future Aspirations - BioPorto aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [8]. - The company expects to achieve positive cash flow in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [8].